Clinical Trial

Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4

Name: Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 — clinical trial record (NCT07522697)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MITO END-4

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

MITO END-4 is a prospective, single arm, multicentric phase II trial aiming to assess whether Inavolisib is effective in the treatment of advanced endometrial carcinoma with pathogenic PIK3CA mutation. Approximately 48 patients with PIK3CA mutation will be overall enrolled in the study.

Trial Details

NCT Number	NCT07522697
Lead Sponsor	National Cancer Institute, Naples
Conditions	Endometrial Cancer
Enrollment	48 participants
Start Date	2026-05
Primary Completion	2030-05 (estimated)
Study Completion	2030-05 (estimated)
Updated on ClinicalTrials.gov	2026-04-13